Ocugen faces a packed 2026-27 catalyst window with filings, interim data and Phase III readouts across three one-time retinal gene therapies.
Zacks·4d ago
More News
Ocugen Stock Outlook: Valuation, Cash Runway and Dilution Risk
Ocugen offers upside from a packed 2026 catalyst calendar, but cash runway limits and dilution risk keep the pre-commercial biotech outlook finely balanced.
Zacks·4d ago
OCGN's Gene-Agnostic Strategy Could Reset Retinal Therapy
Ocugen's gene-agnostic therapy strategy targets broad retinal patient groups with one-time treatments, setting up major 2026-27 catalyst events.
Zacks·4d ago
Ocugen (NASDAQ:OCGN) Shares Gap Down - Should You Sell?
Ocugen (NASDAQ:OCGN) Shares Gap Down - Here's What Happened...
MarketBeat·6d ago
MeiraGTx (MGTX) Soars 6.8%: Is Further Upside Left in the Stock?
MeiraGTx (MGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·6d ago
Ocugen, Inc. (NASDAQ:OCGN) Short Interest Update
Ocugen, Inc. (NASDAQ:OCGN - Get Free Report) was the target of a large growth in short interest in the month of March. As of March 31st, there was short interest totaling 64,754,908 shares, a growth...
MarketBeat·10d ago
Ocugen, Inc. (NASDAQ:OCGN) Given Average Rating of "Moderate Buy" by Analysts
Shares of Ocugen, Inc. (NASDAQ:OCGN - Get Free Report) have received an average rating of "Moderate Buy" from the five ratings firms that are covering the company, Marketbeat Ratings reports. One...
MarketBeat·15d ago
Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells
Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells Biotechs Racing to...
PR Newswire·16d ago
Wall Street Zen Downgrades Ocugen (NASDAQ:OCGN) to Sell
Wall Street Zen downgraded shares of Ocugen from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat·23d ago
Ocugen (OCGN) Up 2.9% Since Last Earnings Report: Can It Continue?
Ocugen (OCGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.